Page 2 - Wes Warnock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alcon Inc. Swiss: Alcon Reports First Quarter 2021 Results Strong commercial execution drives the global launch of new product innovations Substantially completes separation process Full year guidance: sales of $7.8 to $8.0 billion and core diluted EPS of $1.85 to $1.95 Regulatory News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2021. For the first quarter of 2021, worldwide sales were $1.9 billion, an increase of 5% on a reported basis and 2% on a constant currency basis (2), as compared to the same quarter of the ...

Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Builds on company's ophthalmic pharmaceutical manufacturing expertise Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza The acquisition of Simbrinza combined with the company's existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large g...

Press release content from Business Wire. The AP news staff was not involved in its creation. Alcon Shareholders Approve All Binding Resolutions at the 2021 Annual General Meeting April 28, 2021 GMT GENEVA--(BUSINESS WIRE)--Apr 28, 2021-- Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the results of its 2021 Annual General Meeting. Given the global COVID-19 outbreak, Alcon previously directed shareholders to send their voting instructions to the independent representative, Hartmann Dreyer Attorneys-at-Law. Shareholders sh...

Alcon Inc. Investors: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Builds on company's ophthalmic pharmaceutical manufacturing expertise Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza The acquisition of Simbrinza combined with the company's existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma marke...

Alcon Inc. Investors: Alcon Reports Fourth Quarter and Full Year 2020 Results Continued recovery resulted in full year sales of $6.8 billion, 8% below last year New product launches driving market share gains; executing on strategic initiatives Generated $823 million in cash from operations and $350 million in free cash flow Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the fourth quarter and full year ended December 31, 2020. For the fourth quarter of 2020, worldwide sales were $1.9 billion, an increase of 2% on a reported basis and an increase of 1...